Menu
340B stakeholders raised concerns about May 12 draft guidance on the IRA Medicare Drug Price Negotiation Program's “manufacturer effectuation of the maximum fair price in 2026, 2027 and 2028,” among other things.

CMS Offers New Details on Medicare Drug Price Negotiations, 340B Advocates Raise Concerns About Impact on Program

Shannon Young, Associate Editor/Senior Writer 340B Report Views
The Centers for Medicare and Medicaid Services (CMS) released new details this week to help stakeholders navigate the Inflation Reduction [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

Leading 340B and Pharmacy Solutions Firm Maxor Rebrands as ‘VytlOne’

Federal Appellate Court Fast-Tracks Drugmakers’ Appeal of 340B Rebate Ruling

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Quick verification required before signup

Site Footer Live